Key result
Alvimopan, a peripherally acting mu-antagonist, significantly reduced postoperative ileus and length of stay by 12 and 16 hours, respectively, in recent phase III trials.
Why the study?
What are the effective strategies for reducing postoperative ileus in patients after abdominal surgery?
What are the effective strategies for reducing postoperative ileus in patients after abdominal surgery?
A multi-modal postoperative treatment plan involving alvimopan, early ambulation, feeding, and avoiding nasogastric tubes is recommended for the treatment and prevention of postoperative ileus.
Alvimopan may shorten recovery after abdominal surgery; leaves open optimal integration into routine multimodal protocols.
Postoperative Ileus (POI) is a frequent, frustrating occurrence for patients and surgeons after abdominal surgery. Despite significant research investigating how to reduce this multi-factorial phenomenon, a single strategy has not been shown to reduce POI's significant effects on length of stay (LOS) and hospital costs. Perhaps the most significant cause of POI is the use of narcotics for analgesia. Strategies that target inflammation and pain reduction such as NSAID use, epidural analgesia, and laparoscopic techniques will reduce POI but are accompanied by a simultaneous reduction in opioid use. Pharmacologic means of stimulating gut motility have not shown a positive effect, and the routine use of nasogastric tubes only increases morbidity. Recent multi-site phase III trials with alvimopan, a peripherally acting mu-antagonist, have shown significant reductions in POI and LOS by 12 and 16 hours, respectively, by blunting the effects of narcotics on gut motility while sparing centrally mediated analgesia. Use of alvimopan, along with a multi-modal postoperative treatment plan involving early ambulation, feeding, and avoiding nasogastric tubes, will likely be the crux of POI treatment and prevention.
No takes yet. Share an insight, caveat, or question.
A 2008 study conducted a review in Postoperative Ileus. Alvimopan and multi-modal postoperative treatment was evaluated. Alvimopan, a peripherally acting mu-antagonist, significantly reduced postoperative ileus and length of stay by 12 and 16 hours, respectively, in recent phase III trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: